longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

IBIO

IBIO
1.2603.08%( -0.040 )

LongbridgeAI

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

Unusual Whales
Jun 2, 2026 at 11:02 AM
IBIO-600 is a promising long-acting anti-myostatin monoclonal antibody that aims to preserve muscle and enhance body composition. It has been identified as a potential best-in-class candidate in its category.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

iBio

iBio

IBIO.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--